Central Serous Chorioretinopathy and Micropulse Laser Treatment

NCT ID: NCT06346405

Last Updated: 2025-09-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

36 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-05-31

Study Completion Date

2027-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate choroidal and choriocapillaris changes in patients with central serous chorioretinopathy, undergone sub threshold micropulse laser treatment, following any improvement with conservative therapy with Acetazolamide and/or Eplerenone

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Serous Chorioretinopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Subthreshold Micropulse Laser Treatment

Subthreshold micropulse laser treatment consists in 33 spots of 100 microns, distance among each spot of 2.50 microns, duration of 200 sec, power of 250 milliwatt (mW) duty cycle 5%.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of central serous chorioretinopathy (CSC) with no response to conservative therapy, consisted in Acetazolamide and Eplerenone after six months.
* Foveal serous retinal detachment for at least 6 months.
* Minimum age of 18 years old at the screening time
* Reading and comprehension skills of informed consent

Exclusion Criteria

* Previous retinal treatment for CSC, except for Acetazolamide and Eplerenone
* No diffuse retinal epitheliopathy
* Other concomitant ocular diseases, such as age related macular degeneration, diabetic retinopathy, choroidal neovascularization
* Not controlled glaucoma with eyedrops, or advanced glaucoma
* Myopia or hypermetropia greater than 6 diopters
* Opacities of dioptric media
* Low quality of optical coherence tomography (OCT) and OCT-Angiography scans
* Low quality images of Fluorescein angiography and indocyanine green angiography
* No written consensus signed.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Savastano Maria Cristina

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fondazione Policlinico Agostino Gemelli, IRCCS

Roma, R, Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Maria Cristina Savastano, MD, PhD

Role: CONTACT

(+39)063015

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Maria Cristina Savastano, MD, PhD

Role: primary

(+39)063015

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

10

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Optic Nerve Compliance Study
NCT00328835 COMPLETED NA
CPC in Adult Refractory Glaucoma
NCT04921098 UNKNOWN NA